Document is current
Any future updates will be listed below
-
Authors
Nederlof, Iris https://orcid.org/0000-0001-7608-6515
Isaeva, Olga I. https://orcid.org/0000-0001-7377-0944
de Graaf, Manon
Gielen, Robbert C. A. M.
Bakker, Noor A. M.
Rolfes, Adrianne L.
Garner, Hannah https://orcid.org/0000-0002-6804-5040
Boeckx, Bram
Traets, Joleen J. H.
Mandjes, Ingrid A. M.
de Maaker, Michiel
van Brussel, Thomas
Chelushkin, Maksim https://orcid.org/0000-0002-4284-9294
Champanhet, Elisa
Lopez-Yurda, Marta https://orcid.org/0000-0003-3678-3222
van de Vijver, Koen https://orcid.org/0000-0002-2026-9790
van den Berg, José G.
Hofland, Ingrid
Klioueva, Natasja
Mann, Ritse M.
Loo, Claudette E.
van Duijnhoven, Frederieke H.
Skinner, Victoria
Luykx, Sylvia
Kerver, Emile
Kalashnikova, Ekaterina
van Dongen, Marloes G. J.
Sonke, Gabe S. https://orcid.org/0000-0001-8088-9628
Linn, Sabine C. https://orcid.org/0000-0001-5541-0347
Blank, Christian U. https://orcid.org/0000-0002-7945-5846
de Visser, Karin E. https://orcid.org/0000-0002-0293-868X
Salgado, Roberto https://orcid.org/0000-0002-1110-3801
Wessels, Lodewyk F. A. https://orcid.org/0000-0002-1656-6995
Drukker, Caroline A.
Schumacher, Ton N. https://orcid.org/0000-0003-0517-8804
Horlings, Hugo M. https://orcid.org/0000-0003-4782-8828
Lambrechts, Diether https://orcid.org/0000-0002-3429-302X
Kok, Marleen https://orcid.org/0000-0001-9043-9815
-
Funding
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (09150172010043)
Victoria’s Secret Global Fund for Women’s Cancers Rising Innovator Research Grant, in Partnership with Pelotonia & AACR
- License Information
-
More Information
Article History
Received: 2 February 2024
Accepted: 14 August 2024
First Online: 16 September 2024
Competing interests
: R.M.M. reports research grants from Siemens Healhtineers, Bayer Healthcare, Screenpoint Medical, Beckton & Dickinson, PA Imaging, Lunit and Koning, and is an advisory board member for Screenpoint, Bayer, Siemens and Guerbet, all outside the scope of this work. E. Kalashnikova is an employee of Natera. G.S.S. reports research funding to the institute from Merck, Agendia, AstraZeneca, Roche and Novartis and a consulting role for Novartis, Seattle Genetics and Biovica, outside the submitted work. S.C.L. reports research funding to the institute from Roche/Genentech, AstraZeneca, BMS, Tesaro, Merck, Immunomedics, Eurocept Pharmaceuticals, Agendia and Novartis and a consulting role and travel grant from Daiichi Sankyo, outside this work. C.U.B. has received research grants from Novartis, BMS and NanoString, is a paid advisory board member for BMS, MSD, Roche, Novartis, GlaxoSmithKline, AstraZeneca, Pfizer, Lilly, GenMab and Pierre Fabre and holds ownership interest in Uniti Card, Neon Therapeutics and Forty Seven, all outside this submitted work. K.E.d.V. reports research funding from Roche and is a consultant for Macomics, outside the scope of this work. R.S. reports nonfinancial support from Merck and BMS, research support from Merck, Puma Biotechnology and Roche and personal fees from Roche, BMS and Exact Sciences for advisory boards, all outside the scope of this paper. L.F.A.W. reports funding to the institute from Genmab BV. T.N.S. is an advisor for Allogene Therapeutics, Asher Bio, Merus, Neogene Therapeutics and Scenic Biotech; is a stockholder in Allogene Therapeutics, Asher Bio, Cell Control, Celsius, Merus and Scenic Biotech; and is venture partner at Third Rock Ventures, all outside of the current work. M.K. reports research funding to the institute from BMS, Roche and AstraZeneca/MedImmune and an advisory role/speakers’ fee (all compensated to the institute) for Alderaan, BMS, Domain Therapeutics, Medscape, Roche, MSD and Daiichi Sankyo, outside the submitted work. Natera provided nonfinancial support to this study. The other authors declare no competing interests.
